It also helps understand the Glucagon-like Peptide-1 (GLP-1) Agonists clinical trial details, pharmacological action, agreements and collaborations related to Glucagon-like Peptide-1 (GLP-1) Agonists, their approval timelines, patent details, advantages and disadvantages, latest news and press releases
For those who went on to combine the Allurion Programme with the GLP-1 Saxenda (liraglutide), they achieved an average total body weight loss of nearly 19% after approximately 4 months of combined treatment
The FDA considers you clinically obese, and GLP-1 medications are approved for your use regardless of whether you have any other health complications
And so yeah, my goal is always like, I want you to have that foundation of health
However, individual results vary greatly based on your unique physiology